Home > Pressemitteilung: Innovative Battery Materials for Safe ...
The list of reasons to like CrowdStrike is growing, as the contentious world stage increasingly features attacks on digital ...
Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in ...
First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash balance of $31.8 million as of December 31, 2025 ...
Full year 2025 revenue of $71.7 million, up 40%Record full-year operating cash flow of $13.1 million, up 60%Board ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results